A Phase 1 and Pharmacologic Study of MM-111 in Combination With Multiple Treatment Regimens in Patients With Advanced HER2 Positive Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MM 111 (Primary) ; Capecitabine; Cisplatin; Docetaxel; Lapatinib; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions
Sponsors Merrimack Pharmaceuticals

30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.
01 Aug 2014 Status changed from active, no longer recruiting to completed, according to results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com